Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-53.62 M-366.31 M-20.03 M-111.24 M136.49 M-414.24 M339.52 MFlux de trésorerie liés aux activités de financement181.12 M-48 K-18.65 M-18.73 M-526.45 M-42.39 M809.55 MFlux de trésorerie disponible85.36 M304.54 M175.9 M159.26 M572.84 M717.02 M759.12 M
BioMarin Pharmaceutical Inc. - Common Stock
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.